RxDoctor Payments Data

Paul Jew, MD

Family Medicine · Amarillo, TXNPI 1114086253

Payments from drug & device makers

$3,071in general payments, 2019–2025

Across 146 payments — averaging $21.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$898
  • Boehringer Ingelheim$630
  • Pfizer$481
  • Lilly USA, LLC$287
  • Bayer$185
  • Merck$137
  • plus $454 from 9 others

What the payments were for

  • Food & beverage$3,05499%
  • Education$171%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,071 in reported general payments places this provider in the 80th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$56,413
Medicare patients
195
Services billed
749

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol47$52,798
JardianceEmpagliflozin44$51,744
JanumetSitagliptin Phos/Metformin Hcl27$28,761
TrulicityDulaglutide19$27,609
MounjaroTirzepatide16$23,693
Janumet XrSitagliptin Phos/Metformin Hcl12$16,499
Bydureon BciseExenatide Microspheres13$14,290
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$7,764
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog13$5,355
LantusInsulin Glargine,hum.Rec.Anlog16$2,311
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide51$1,908
Levothyroxine Sodium155$1,849
Lantus SolostarInsulin Glargine,hum.Rec.Anlog15$1,839
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide55$1,806
Febuxostat11$1,571

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$898$52,79847 claims
Boehringer IngelheimJardiance$630$51,74444 claims
Lilly USA, LLCTrulicity, Mounjaro$287$51,30135 claims
MerckJanumet, Janumet Xr$137$45,26039 claims
GSKTrelegy Ellipta$13$7,76412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Amarillo

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →